Core Viewpoint - Frontier Biotech (688221) has announced a restricted stock incentive plan for 2025, aiming to attract and retain talent while enhancing the company's core competitiveness and achieving strategic goals [1] Group 1: Incentive Plan Details - The plan includes granting a total of 5 million restricted stocks, with 4.25 million for initial grants and 750,000 reserved, at a price of 8.56 yuan per share [1] - The initial grant will be distributed among 27 employees, representing 8.94% of the total workforce of 302 as of December 31, 2024 [2] - 16 out of the 27 recipients are assessed based on R&D metrics, receiving 3.07 million shares, which accounts for 61.40% of the total shares granted [2] Group 2: Performance Targets - For the first vesting period in 2025, the company must achieve at least one IND application and eight new drug patent applications to meet the 100% vesting requirement [2] - For the second vesting period in 2026, the cumulative targets include five IND applications and 16 new drug patent applications, along with one BD transaction for small nucleic acid drugs [3] - Revenue growth targets are set at a minimum of 10% for 2025 and a cumulative growth of 30% for 2025-2026, based on 2024 revenue [3] Group 3: Focus on Small Nucleic Acid Drugs - The incentive plan emphasizes achieving BD transactions for small nucleic acid drugs, highlighting the company's focus in this area [4] - Frontier Biotech has developed a comprehensive and high-standard development system for small nucleic acid drugs, leveraging internal and external collaborations [4] - The company is advancing multiple drug candidates in various therapeutic areas, including IgA nephropathy and metabolic diseases, all currently in preclinical stages [4] Group 4: Technological Innovations - The company has developed a proprietary siRNA delivery vehicle, ACORDE, which is currently under international patent application [5] - The strategic focus is on innovative drug development and commercialization, marking a critical phase for high-quality business growth [5] - The performance metrics of the incentive plan align with the company's strategic needs and are designed to enhance competitiveness and employee motivation [5]

Core Viewpoint - Frontier Biotech (688221.SH) announced a restricted stock incentive plan for 2025, aiming to enhance employee motivation and align interests with shareholders [1] Summary by Sections Incentive Plan Details - The incentive plan proposes to grant a total of 5 million restricted stocks, accounting for approximately 1.33% of the company's total share capital as of the announcement date [1] - Of the total, 4.25 million restricted stocks will be granted initially, representing about 1.13% of the total share capital and 85% of the total stocks to be granted [1] - An additional 750,000 stocks are reserved, which is about 0.20% of the total share capital and 15% of the total stocks to be granted [1]

Group 1 - The core point of the article is that Frontier Biotech (688221.SH) has announced a draft for a restricted stock incentive plan for 2025, proposing to grant 5 million restricted shares, which accounts for approximately 1.33% of the company's total share capital as of the announcement date [1] - The plan includes an initial grant of 4.25 million restricted shares and reserves 750,000 shares for future grants [1] - The grant price for the initial restricted shares is set at 8.56 yuan per share [1] Group 2 - The effective period of the incentive plan is from the date of grant until all granted restricted shares are vested or become invalid, with a maximum duration of 36 months [1]

Group 1 - The core point of the article is that Frontier Bio (688221.SH) has announced a draft for a restricted stock incentive plan for 2025, proposing to grant 5 million shares, which accounts for approximately 1.33% of the company's total share capital as of the announcement date [1] - The plan includes an initial grant of 4.25 million shares and reserves 750,000 shares for future grants [1] - The grant price for the initial restricted stock is set at 8.56 yuan per share [1] Group 2 - The effective period of the incentive plan is from the date of grant until all granted restricted stocks are vested or become invalid, with a maximum duration of 36 months [1]

Group 1 - The company, Qianyan Bio, announced an incentive plan involving 27 individuals, with a total of 5 million restricted shares to be granted, representing approximately 1.33% of the company's total share capital of about 375 million shares [1] - The grant price for the restricted shares is set at 8.56 yuan per share, with a validity period of up to 36 months from the date of grant [1] - For the year 2024, the company's revenue composition is projected to be 97.13% from the pharmaceutical manufacturing industry and 2.87% from other businesses [1] Group 2 - As of the latest report, the market capitalization of Qianyan Bio is 5.6 billion yuan [2]

前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划（草案） 前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划（草案） 二〇二五年九月 前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划（草案） 证券简称：前沿生物 证券代码：688221 声明 二、前沿生物 2025 年限制性股票激励计划（以下简称"本激励计划"）采 取的激励形式为第二类限制性股票。股票来源为公司向激励对象定向发行的本公 司人民币 A 股普通股股票。 符合本激励计划授予条件的激励对象，在满足相应归属条件和归属安排后， 在归属期内以授予价格获得公司 A 股普通股股票，该等股票将在中国证券登记 结算有限责任公司上海分公司进行登记。在激励对象获授的限制性股票归属前， 激励对象不享有公司股东权利，且上述限制性股票不得转让、用于担保或偿还债 务等。 三、本激励计划拟授予激励对象的限制性股票数量为 500.00 万股，约占本 激励计划草案公布日公司股本总额 37,457.8653 万股的 1.33%。其中，首次授予 限制性股票 425.00 万股，约占本激励计划草案公布日公司股本总额 37,457.8653 万股 ...

证券代码：688221 证券简称：前沿生物 公告编号：2025-033 前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划（草案）摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股权激励方式：第二类限制性股票。 股份来源：前沿生物药业（南京）股份有限公司（以下简称"前沿生物" "公司"或"本公司"）向激励对象定向发行的本公司人民币 A 股普通股股票。 下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市 公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股 票上市规则》（以下简称"《上市规则》"）《科创板上市公司自律监管指南第 4 号 ——股权激励信息披露》（以下简称"《自律监管指南》"）等有关法律、行政法规、 规范性文件以及《公司章程》的规定，公司制定了本激励计划。 截至本激励计划草案公布日，公司不存在同时实施其他股权激励计划以及其 他长期激励机制的情形。 二、股权激励方式及标的股票来源 （一）本激励计划拟授出的权益形式 本激励计划采 ...

前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划首次授予激励对象名单 一、 2025 年限制性股票激励计划的分配情况 2、本激励计划首次授予激励对象不包括公司独立董事、监事、单独或合计持有公司 5%以上 股份的股东或实际控制人及其配偶、父母、子女。 3、预留部分的激励对象应当在本激励计划经股东大会审议通过后 12 个月内确定，经董事会 提出、薪酬与考核委员会/监事会发表明确意见、律师发表专业意见并出具法律意见书后，公司在 指定网站按要求及时准确披露激励对象相关信息。 4、合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 前沿生物药业（南京）股份有限公司 董事会 2025 年 9 月 17 日 | 姓名 | 职务 | 国籍 | 获授的第二类限 制性股票数量 | 占本激励计划拟 授出全部权益数 | 占本激励计划草 案公布日股本总 | | --- | --- | --- | --- | --- | --- | | | | | （万股） | 量的比例 | 额的比例 | | 一、高级管理人员 | | | | | | | 高千雅 | 副总经理、 董事会秘书 | 中国 | 50.00 | ...

关于前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划（草案）的 法律意见书 国枫律证字[2025]AN147-1 号 GRANDWAY 北京国枫律师事务所 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层 邮编: 100005 电话（Tel）: 010-88004488/66090088 传真（Fax）: 010-66090016 目 | 释 义. | | --- | | 一、 公司实施本次激励计划的主体资格 | | 二、 《激励计划(草案)》内容的合法合规性……………………………………………………………………………… 7 | | 三、 本次激励计划应履行的法定程序……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………20 | | 四、 本次激励计划激励对象的确定 | | 五、 本次激励计划的信息披露 ……………………………………………………………………… ...

前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划实施考核管理办法 前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划 实施考核管理办法 第一条 考核目的 制定本办法的目的是加强本激励计划执行的计划性，量化本激励计划设定的 具体目标，促进激励对象考核管理的科学化、规范化、制度化，确保实现本激励 计划的各项业绩指标；同时引导激励对象提高工作绩效，提升工作能力，客观、 公正评价员工的绩效和贡献，为本激励计划的执行提供客观、全面的评价依据。 第二条 考核原则 （一）坚持公平、公正、公开的原则，严格按照本办法考核评估激励对象； （二）考核指标与公司中长期发展战略、年度经营目标结合；与激励对象工 作业绩、工作能力和工作态度结合。 第 1 页 共 6 页 前沿生物药业（南京）股份有限公司 2025 年限制性股票激励计划实施考核管理办法 前沿生物药业（南京）股份有限公司（以下简称"公司"或"前沿生物"） 为进一步完善公司法人治理结构，建立、健全公司长效激励约束机制，吸引和留 住优秀人才，充分调动其积极性和创造性，有效提升核心团队凝聚力和企业核心 竞争力，有效地将股东、公司和核心团队三方利益结合在 ...